Table 4.

Factors associated with the occurrence of acute rejection.

	Univariate analysis		Multivariate analysis
	HR (95% CI)	P-value	HR (95% CI)	P-value
Female (vs. Male)	1.05 (0.76–1.45)	0.76	NA	NA
Cyclosporin (vs. tacrolimus)	1.22 (0.87–1.70)	0.25	NA	NA
PP number	1.09 (1.04–1.14)	<0.01	1.01 (0.94–1.08)	0.83
Rituximab dose=0 mg	Reference
100–299 mg	1.22 (0.91–1.65)	0.19	NA	NA
300–500 mg	1.36 (0.93–1.98)	0.11	NA	NA
BK viremia PCR ≥4 logs	1.54 (1.23–1.94)	<0.01	NA	NA
CMV viremia PCR ≥4 logs	1.81 (1.46–2.24)	<0.01	NA	NA
Urinary tract infection	1.25 (0.92–1.69)	0.16	NA	NA
Pneumonia	2.00 (1.41–2.86)	<0.01	NA	NA
Combined infection*	1.89 (1.47–2.43)	<0.01	1.91 (1.45–2.51)	<0.01
ABOc & HLAc	Reference
ABOc & HLAi	1.29 (0.87–1.90)	0.20	1.90 (0.79–4.57)	0.15
ABOi & HLAc	1.22 (0.89–1.66)	0.22	1.22 (0.83–1.78)	1.22
ABOi & HLAi	1.93 (1.05–3.55)	0.34	2.63 (1.04–6.65)	0.04
HLA-compatible	Reference
CDC-positive	3.13 (1.61–6.09)	<0.01	1.25 (0.39–4.04)	0.71
FCXM-positive	1.08 (0.72–1.63)	0.72	0.52 (0.21–1.34)	0.52

PP – plasmapheresis; CMV – cytomegalovirus; ABOc – ABO-compatible; ABOi – ABO-incompatible; HLA – human leukocyte antigen; CDC – complement-dependent cytotoxicity; FCXM – flow-cytometric crossmatch; DSA – donor-specific antibody.

^*Combined infection consisted of BK viremia PCR ≥4 logs, CMV viremia PCR ≥4 logs, urinary tract infection, and pneumonia.